Zobrazeno 1 - 10
of 248
pro vyhledávání: '"J Michael Dixon"'
Autor:
Mohammed Inayatullah, Arun Mahesh, Arran K Turnbull, J Michael Dixon, Rachael Natrajan, Vijay K Tiwari
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 4, Pp 823-853 (2024)
Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by extensive intratumoral heterogeneity, high metastasis, and chemoresistance, leading to poor clinical outcomes. Despite progress, the mechanis
Externí odkaz:
https://doaj.org/article/f9d72b0bea3548a1b9749e30da03cd30
Publikováno v:
Breast, Vol 66, Iss , Pp 305-309 (2022)
Background: Mondor's disease is a rare disorder characterised by thrombosis of superficial veins within the subcutaneous tissue of the breast and other organs. While factors such as trauma, infection, physical exertion, breast cancer and breast surge
Externí odkaz:
https://doaj.org/article/2d1eec698800450788ff30cd43403d9b
Autor:
Carlos Martínez-Pérez, Jess Leung, Charlene Kay, James Meehan, Mark Gray, J Michael Dixon, Arran K Turnbull
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 7, p 618 (2021)
Novel biomarkers are needed to continue to improve breast cancer clinical management and outcome. IL6-like cytokines, whose pleiotropic functions include roles in many hallmarks of malignancy, rely on the signal transducer IL6ST (gp130) for all their
Externí odkaz:
https://doaj.org/article/27cbca283aef426884f60112c5af705a
Autor:
Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart, Christos Sotiriou
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0216175 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0053292.].
Externí odkaz:
https://doaj.org/article/d71c1eb6584e47cfbf6051eab8cecf7c
Autor:
Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart, Christos Sotiriou
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53292 (2013)
The phosphatidylinositol 3' kinase (PI3K) pathway is commonly activated in breast cancer and aberrations such as PI3K mutations are common. Recent exciting clinical trial results in advanced estrogen receptor-positive (ER) breast cancer support mTOR
Externí odkaz:
https://doaj.org/article/6b52976f3af14e91b6fddd339081c482
Autor:
J Michael Dixon
Publikováno v:
Canadian Journal of Infectious Diseases, Vol 2, Iss Suppl A, Pp 1-2 (1991)
Externí odkaz:
https://doaj.org/article/b1ec525d07134d468f364465ff92a51f
Publikováno v:
Cancer Research. 83:PD10-09
Background: 80% of all breast cancers (BCs) are ER-positive (ER+). Not all respond to adjuvant endocrine therapy (aET) and a significant number develop endocrine resistance and recur. The basis for primary and acquired endocrine resistance is poorly
Autor:
Anja van de Stolpe, Cornelis J.H. van de Velde, Judith R. Kroep, Wim Verhaegh, J. Michael Dixon, Arran K. Turnbull, Andrew H. Sims, John W.M. Martens, Bart van der Burg, Susan Kloet, Elma Meershoek-Klein Kranenbarg, Sevgi E. Fruytier, Anne van Brussel, Eveline C. den Biezen-Timmermans, Ayoub Charehbili, Peter J.K. Kuppen, Erik J. Blok, Márcia A. Inda
Supplemental methods on estradiol measurements and sample analysis. Supplemental tables: 1. Public datasets used; 2. Estrogen concentrations on breast tissue; 3. Association of baseline parameters and ERPAS (Edinburgh cohort); 4. Logistic regression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50dd21e77f29c9ec8399f858f46f98f9
https://doi.org/10.1158/1535-7163.22510236.v1
https://doi.org/10.1158/1535-7163.22510236.v1
Autor:
Anja van de Stolpe, Cornelis J.H. van de Velde, Judith R. Kroep, Wim Verhaegh, J. Michael Dixon, Arran K. Turnbull, Andrew H. Sims, John W.M. Martens, Bart van der Burg, Susan Kloet, Elma Meershoek-Klein Kranenbarg, Sevgi E. Fruytier, Anne van Brussel, Eveline C. den Biezen-Timmermans, Ayoub Charehbili, Peter J.K. Kuppen, Erik J. Blok, Márcia A. Inda
Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of response to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48b4f06713dad953982cc15f8a6c41e3
https://doi.org/10.1158/1535-7163.c.6539547.v1
https://doi.org/10.1158/1535-7163.c.6539547.v1
Autor:
Arran Turnbull, J. Michael Dixon, Lisa A. Carey, Charles M. Perou, Joel S. Parker, James Meehan, Mark Gray, Charlene Kay, Carlos Martinez-Perez, Lorna Renshaw, Xiaping He, Youli Xia
Supplementary Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37bfbd200f4a48ae4b320c6fa014db22
https://doi.org/10.1158/1078-0432.22488159
https://doi.org/10.1158/1078-0432.22488159